Eruptive Sebaceous Hyperplasia: A Case Report and Review of the Literature

Carsten Z Steinmetz, MS1; Amanda Getz, MS, MD2; Andras Schaffer, MD3; Stephen K Richardson, MD3

Abstract

Introduction
Eruptive sebaceous hyperplasia (ESH) is a benign process characterized by the acute onset and rapid proliferation of sebaceous glands, typically on the face. Although historically attributed to cyclosporine therapy, the preponderance of reports over the past 2 decades suggests a more complex etiology. There is increasing thought a combination of multiple medications as well as a genetic component contribute to ESH’s clinical presentation. Despite these theories, the exact cause of ESH in immunosuppressive therapy is poorly understood.

Case Presentation
To our knowledge, we report the third case of ESH arising in multimodality immunosuppressive therapy, consisting of tacrolimus, mycophenolate mofetil, and prednisone, affecting a renal transplant patient. Our patient began cyclosporine monotherapy at an early age but did not see eruption of lesions until years later after following a multimodal therapy.

Conclusion
We discuss the association of ESH with other medical conditions and treatments. We hope this case sheds light on a possible complication of multimodal immunosuppressive therapy in renal transplant patients. This will allow patients and providers to be better informed of the pros and cons of different treatment options for immunosuppressive therapy in renal transplant patients.

Keywords
cyclosporine; eruptive sebaceous hyperplasia; sebaceous gland diseases; immunosuppression therapy; mycophenolate mofetil; prednisone; renal transplant; sebocytes; tacrolimus
### Table 1. Cases of ESH Reported in the English Medical Literature

<table>
<thead>
<tr>
<th>Reference</th>
<th>Age/Sex</th>
<th>Medications</th>
<th>History</th>
</tr>
</thead>
</table>
| Marini et al, 2001   | 41/M    | • Cyclosporine (3 mg/kg qd) • Prednisone (unknown dose) | Bone marrow transplant  
Chronic myeloid leukemia  
ESH developed 5 years after BMT |
| Boschnakow et al, 2003 | 33/M    | • Cyclosporine (2 mg/kg qd) • Prednisolone (0.07 mg/kg qd) for 10 years | Renal transplant  
ESH developed 9 years after first kidney transplant |
|                      | 66/M    | • Cyclosporine (2.5 mg/kg qd) • Prednisolone (0.06 mg/kg qd) for 23 years | Renal transplants (1978, 1991)  
ESH developed 7 years after second kidney transplant |
| Yamamoto et al, 2009  | 68/M    | • Medically managed  
• No immunosuppression or transplant history | Chronic renal failure  
(Cr 7.8 mg/dl, BUN 82 mg/dl)  
ESH developed prior to hemodialysis |
|                      | 58/M    | • Managed with dialysis  
• No immunosuppression or transplant history | Chronic renal failure  
(Cr 12.3 mg/dl, BUN 97 mg/dl)  
ESH developed after initiation of dialysis |
| Yayli et al, 2010    | 55/M    | • Cyclosporine (5 mg/kg qd) with gradual reduction over 1 year (to 2 mg/kg qd) • Prednisolone (unknown dose) for 9 years | Renal transplant  
ESH developed 4 years into treatment |
| McDonald et al, 2011 | 36/M    | • Cyclosporine (60 mg bid)  
• Azathioprine (75 mg qd)  
• Prednisolone (5 mg qd)  
• Doxycycline (50 mg qd) | Renal transplant  
ESH developed 15 years into cyclosporine, azathioprine, and prednisolone treatment.  
Patient was taking doxycycline for rosacea during presentation of ESH |
|                      | 45/M    | • Cyclosporine for 9 years, then discontinued  
• Prednisolone (5 mg qd), followed by  
• Tacrolimus (3 mg bid)  
• Mycophenolate mofetil (1.5 g qd)  
• Doxycycline (50 mg qd) | Renal transplants (1991, 2003)  
ESH developed during cyclosporine treatment; lesions increased in number after discontinuation of cyclosporine and initiation of prednisone/tacrolimus/mycophenolate mofetil |
| Cortés et al, 2016   | 69/M    | • Cyclosporine (350 mg qd) | Bone marrow transplant  
Acute myeloid leukemia  
ESH developed 7 months after initiation of cyclosporine |
| Jung et al, 2016     | 40/M    | • Cyclosporine (350 mg qd) • Prednisolone (7.5 mg qd) for 11 years followed by  
• Tacrolimus (6 mg qd)  
• Prednisolone (5 mg qd) for 4 years | Renal transplant  
ESH developed during treatment with cyclosporine and prednisolone; lesions increased in number after discontinuation of cyclosporine and initiation of tacrolimus and prednisolone therapy |
| Levandoski et al, 2017 | 29/M    | • Tacrolimus (6 mg bid),  
• Mycophenolate mofetil (500 mg qid)  
• Prednisone (20 mg qd) | Renal transplants (2006, 2015)  
ESH developed 2 weeks after initiation of immunosuppressive therapy |
| Ranasinghe et al, 2018 | 46/M    | • Prednisone (40 mg qd)  
• Long standing cholestyramine and mercaptopurine therapy | Crohn’s disease  
ESH developed two weeks after starting prednisone therapy |
| Steinmetz et al, 2023| 38/M    | • Cyclosporine (unknown dose) during childhood, discontinued 20+ years ago  
• Prednisone (5 mg qd)  
• Tacrolimus (0.5 mg qd)  
• Mycophenolate sodium (360 mg qd)  
• Amlodipine (5 mg qd)  
• Febuxostat (40 mg qd)  
• Terazosin (2 mg daily) | Renal transplants (1984, 2007)  
ESH developed 2-3 years ago (10 years after initiating immunosuppressive therapy consisting of tacrolimus, prednisone and mycophenolate sodium |
amination was notable for numerous pink-yellow papules with central umbilication diffusely distributed over his entire face (Figure 1). Currently, there is no definitive treatment for ESH. All treatment is purely cosmetic. A biopsy of a characteristic lesion showed histologic findings consistent with sebaceous hyperplasia (Figure 2).

Discussion
To date, 13 cases of ESH have been reported in the English medical literature. All cases affected men either being managed for chronic renal failure (CRF) or being treated with systemic immunosuppressive medications in the setting of allogeneic transplantations (renal and bone marrow) and autoimmune disease (ie, Crohn’s disease). Of note, patients with existing or pre-existing renal disease (eg, chronic renal failure and renal disease resulting in transplantation) accounted for the majority (10/13; 77%) of cases, both in the presence or absence of immunosuppression. The predominance of ESH among adult men has been attributed to undefined genetic factors and unique characteristics of the pilosebaceous unit.4-7 In support of this assertion, no cases of ESH have been reported among women (or children). An autosomal dominant pattern has also been reported within families, suggesting a heritable component.5 At the onset of his ESH, our patient was on a multimodal immunosuppressive regimen consisting of tacrolimus, mycophenolate mofetil, and prednisone. Among all reported cases, ESH arose or was exacerbated in the setting of this regimen (3/13; 23% of patients; Figure 3). Among patients with pre-existing ESH attributed to the use of cyclosporine (2/13; 15% of cases), those treated with this combination of medications experienced a worsening of their condition. In both cases, tacrolimus, mycophenolate mofetil, and prednisolone were substituted for cyclosporine (with or without prednisolone), suggesting that these medications were suffi-

Figure 1. A 38-year-old male presented with numerous pink-yellow papules diffusely distributed over his face.

Figure 2. A shave biopsy of a representative lesion shows the superficial portion of enlarged mature sebaceous glands (orange arrows) in close proximity to the epidermis and a follicular unit (HE stain, 10x magnification).
icient to sustain the proliferation of sebaceous glands in the absence of cyclosporine. In our case report, cyclosporine was administered after the patient’s first transplant (during early childhood) and discontinued decades before the onset of his cutaneous findings, suggesting either an unlikely delayed reaction to cyclosporine or a response to the multimodal regimen.

It has been hypothesized that lipophilic drugs (such as cyclosporine, prednisone, and tacrolimus) promote their accumulation in sebaceous glands, stimulating hyperplasia. Tacrolimus and cyclosporine share many physiochemical properties. Both are calcineurin inhibitors that suppress the production of proinflammatory cytokines. The high lipid solubility of these drugs promotes their accumulation in the skin, resulting in abnormal epithelial cell proliferation. It has also been postulated that the effect of prednisone on the reduction of systemic androgens leads to a reduction in sebocyte turnover. The absence of any reported cases of ESH associated with prednisone monotherapy suggests that prednisone alone is not sufficient to induce this condition.

We have presented a novel report on ESH arising in the setting of mycophenolate monotherapy. Through our literature search, we could not identify another case quite like ours. Among reported cases, it has always been prescribed with tacrolimus, either in combination with or without prednisone. Because systemic tacrolimus is rarely used as a monotherapy, it is difficult to determine the full extent of its contribution to ESH pathogenesis.

It is difficult to draw a definitive link between ESH and specific disease states. However, there does appear to be an association between ESH and renal failure (Figure 4). Two cases of ESH were reported in patients with chronic renal failure (in the absence of immu-
nosuppressive therapy or renal transplantation). In one case, the patient was being treated with hemodialysis. It has been postulated that the interaction between blood and the dialytic membrane releases cytokines that stimulate sebocyte proliferation.2

Although 1 case of ESH was reported in a patient afflicted with Crohn’s disease, there have been no other reports of ESH arising in the setting of inflammatory bowel disease. We suspect the patient’s immunosuppressive regimen (prednisone and mercaptopurine) may have contributed to the onset of his ESH. In this case, the authors hypothesized that decreased androgen production due to prednisone therapy, age, and drug deposition in the sebaceous glands predisposed the patient to this condition.3

To date, there are no definitive treatments available for ESH. Management is aimed at cosmetic improvement. Strategies encompass those currently used to manage sebaceous hyperplasia, ranging from destructive techniques (eg, electrocautery, cryotherapy, CO2 laser) to systemic treatments (eg, isotretinoin), and photodynamic therapy.10

Conclusion
ESH appears to be a disease limited to men and is strongly associated with drug-induced immnosuppression in multiple clinical settings. These drugs include cyclosporine, prednisone, mycophenolate mofetil, and tacrolimus. Further study is warranted to characterize the complex interactions and mechanisms underlying the onset and progression of ESH in the setting of renal disease, allogeneic transplantation, and other systemic inflammatory disorders requiring immunosuppression.

Conflicts of Interest
The authors declare they have no conflicts of interest.

Author Affiliations
1. Edward Via College of Osteopathic Medicine, Spartanburg, SC
2. Florida State University College of Medicine, Tallahassee, FL
3. Dermatology Associates of Tallahassee, Tallahassee, FL

References